pexmetinib   Click here for help

GtoPdb Ligand ID: 9917

Synonyms: ARRY-614 | ARRY614
Compound class: Synthetic organic
Comment: Pexmetinib is an orally bioavailable small-molecule inhibitor of p38 MAPK (β isoforms) and Tie2 kinases [2]. It is a type 2 kinase inhibitor that binds both Tie2 and p38 MAP kinases in the "DFG-out" conformation. p38 MAPK is a proinflammatory kinase, Tie2 is an endothelial cell specific receptor tyrosine kinase and is the receptor for angiopoietin-1. Concomitant inhibition of these kinases is predicted to produce antineoplastic, anti-inflammatory and antiangiogenic effects that would provide a novel anti-cancer therapeutic, in particular for the treatment of myelodysplastic syndromes (MDS) [1,4] and acute myeloid leukemia (AML).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 105.71
Molecular weight 556.26
XLogP 5.49
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OCCn1ncc2c1ccc(c2)Oc1ccc(cc1CNC(=O)Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)F
Isomeric SMILES OCCn1ncc2c1ccc(c2)Oc1ccc(cc1CNC(=O)Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)F
InChI InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)
1. Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A. (2013)
Signal transduction inhibitors in treatment of myelodysplastic syndromes.
J Hematol Oncol, 6: 50. [PMID:23841999]
2. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S et al.. (2016)
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cancer Res, 76 (16): 4841-4849. [PMID:27287719]
3. Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M et al.. (2015)
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Clin Cancer Res, 21 (5): 985-94. [PMID:25480830]
4. Gañán-Gómez I, Bohannan ZS, Garcia-Manero G. (2015)
p38 MAPK in MDS.
Aging (Albany NY), 7 (6): 346-7. [PMID:26081220]